Clinical Trial Detail

NCT ID NCT01184326
Title An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

kidney cancer

Advanced Solid Tumor

Therapies

Everolimus + Pazopanib

Age Groups: adult

No variant requirements are available.